Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sunshine Biopharma, Inc. (SBFM : NSDQ)

• Company Description    Sunshine Biopharma Inc. is a pharmaceutical company. It focused on the research, development and commercialization of oncology and antiviral drugs. Sunshine Biopharma Inc. is based in MONTREAL. Number of Employees: 50

• Price / Volume Information    Yesterday's Closing Price: $1.14 Daily Weekly Monthly 20 Day Moving Average: 680,466 shares Shares Outstanding: 3.88 (millions) Market Capitalization: $4.42 (millions) Beta: 1.17 52 Week High: $24.30 52 Week Low: $1.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.56% -6.14% 12 Week -50.00% -51.06% Year To Date -90.73% -91.78%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 333 LAS OLAS WAY CU4 SUITE 433 - FORT LAUDERDALE,FL 33301 USA ph: 954-330-0684 fax: - investors@sunshinebiopharma.com https://sunshinebiopharma.com

• General Corporate Information    Officers Steve N. Slilaty - Chief Executive Officer Camille Sebaaly - Chief Financial Officer David Natan - Director Andrew Keller - Director Rabi Kiderchah - Director Peer Information Sunshine Biopharma, Inc. (CORR.) Sunshine Biopharma, Inc. (RSPI) Sunshine Biopharma, Inc. (CGXP) Sunshine Biopharma, Inc. (BGEN) Sunshine Biopharma, Inc. (GTBP) Sunshine Biopharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 867781809 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/12/26 Share - Related Items Shares Outstanding: 3.88 Most Recent Split Date: 6.00 (0.10:1) Beta: 1.17 Market Capitalization: $4.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.95 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.10 Price/Cash Flow: - Price / Sales: 0.13 EPS Growth vs. Year Ago Period: 70.51% vs. Previous Quarter: 54.00% Sales Growth vs. Year Ago Period: -1.55% vs. Previous Quarter: 14.53% ROE 06/30/26 - -26.36 03/31/26 - -27.75 12/31/25 - -27.14 ROA 06/30/26 - -20.60 03/31/26 - -21.57 12/31/25 - -21.14 Current Ratio 06/30/26 - 5.46 03/31/26 - 4.22 12/31/25 - 4.17 Quick Ratio 06/30/26 - 3.30 03/31/26 - 1.98 12/31/25 - 2.08 Operating Margin 06/30/26 - -17.94 03/31/26 - -18.45 12/31/25 - -17.86 Net Margin 06/30/26 - -17.94 03/31/26 - -18.45 12/31/25 - -17.86 Pre-Tax Margin 06/30/26 - -15.73 03/31/26 - -16.84 12/31/25 - -16.40 Book Value 06/30/26 - 11.52 03/31/26 - 43.83 12/31/25 - 46.93 Inventory Turnover 06/30/26 - 1.87 03/31/26 - 1.77 12/31/25 - 1.84 Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©